Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone
Information source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post Operative Pain; Hyperalgesia
Intervention: ketamine infusion (Drug); Methadone PCA (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Official(s) and/or principal investigator(s): Emiliano Tognoli, Principal Investigator, Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori
Overall contact: Emiliano Tognoli, Phone: 02/23902176, Email: Emiliano.Tognoli@istitutotumori.mi.it
Summary
Background: In perioperative period inhibition of N-Methyl-D-Aspartate receptor prevents
opioid-induced hyperalgesia and reduce postoperative opioid requirement after abdominal
surgery. Methadone is both a µ-opioid receptor agonist like Morphine and a
N-Methyl-D-Aspartate antagonist. Study Aim. To evaluate the efficacy of intraoperative
Ketamine and postoperative Methadone analgesia in preventing opioid-induced hyperalgesia
after abdominal surgery.
Clinical Details
Official title: Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: the extent of hyperalgesia area proximal to surgical wound
Secondary outcome: pain intensityopioids related adverse events
Detailed description:
not desired
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients undergoing open colo-rectal surgery
Exclusion Criteria:
- ASA status more than II, history of chronic pain, ischemic heart disease or chronic
pulmonary disease, allergy to any drugs used in the protocol. Body Max Index more
than 35.
Locations and Contacts
Emiliano Tognoli, Phone: 02/23902176, Email: Emiliano.Tognoli@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20133, Italy; Recruiting Emiliano Tognoli, Principal Investigator
Additional Information
Starting date: December 2009
Last updated: May 15, 2012
|